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Lesion severity and treatment complexity are
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inguinal intervention
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Rachid Benjeloun, MD, Evan J. Ryer, MD, Craig Kent, MD, and Peter L. Faries, MD, New York, NY
Objectives: Percutaneous revascularization has become increasingly utilized for the treatment of lower extremity ischemia.
Patients with limb-threat have been shown to be at increased risk of failure, although the reasons for this remain unclear.
This study analyzed factors associated with percutaneous treatment failure, focusing specifically on lesion characteristics
and treatment complexity.
Methods:We retrospectively reviewed percutaneous infra-inguinal interventions performed for peripheral occlusive disease
between 2002 and 2005 using a prospectively maintained database. Lesion characteristics were assessed by angiography,
and lesions were graded according to the TransAtlantic InterSociety Consensus (TASC) criteria. Patency was expressed
by Kaplan-Meier method and compared by log-rank analysis. Multivariate Cox-regression analysis was used to assess
significant factors on univariate analysis. Mean follow-up was 11.8 months.
Results: A total of 324 interventions for claudication (55.8%), rest pain (18.4%), or tissue loss (25.8%) were analyzed,
including 284 primary interventions and 40 re-interventions in 258 patients (mean age 72.1  10 years, 51.0% male).
TASC lesion grades included: A (4.9%), B (29.3%), C (37.7%), and D (28.1%). Isolated single-level interventions
(femoral, popliteal, or tibial) were performed in 38.9%, while two-level interventions were performed in 46.2% and
three-level interventions in 14.9%. Overall primary patency ( SD) at 6, 12, and 18 months was 87  2%, 66  2% and
59  4%, respectively. Secondary patency at 6, 12, and 18 months was 89  2%, 76  3%, and 69  5%. One-year limb
salvage rate (limb-threat patients) was 85  3%. Limb-threatening ischemia as the indication for intervention was most
highly associated with failure of both primary and secondary patency and was associated with four indicators of lesion
severity and treatment complexity, including increasing TASC grade, multilevel intervention, tibial intervention, and
reduced tibial outflow. One-year primary patency was inversely correlated with TASC severity (TASC A-C: 67  6%, D:
61 4%; P< .05), multilevel intervention (76 5% and 49 9% for single vs multilevel, P .002), distal interventions
(74  5% and 57  7% for femoral vs tibial, P < .05), and decreased tibial runoff (83  6% and 52  6% for three- vs <
three-vessels, P < .02). No differences in secondary patency or limb-salvage rates existed for these lesion- and
treatment-related variables. Multilevel intervention and tibial intervention remained significant independently associated
with primary patency on multivariate analysis.
Conclusions: Patients with limb-threatening ischemia are at increased risk of initial failure compared with claudicants,
likely as a result of the increased prevalence of advanced lesion severity and treatment complexity, which are associated
with decreased primary patency. However, this finding did not extend to secondary patency or limb-salvage in the overall
patient population. Although additional studies with longer follow-up are needed, these findings argue that percutaneous
intervention may still be considered as a primary treatment modality with the understanding that these patients may have
higher re-intervention rates and may ultimately require salvage open surgical bypass for persistent failures of percutane-
ous therapy. (J Vasc Surg 2007;46:709-16.)Chronic lower extremity ischemia is a common mani-
festation of peripheral vascular disease and can result in
morbidity ranging from claudication to limb loss. Mainstay
of therapy for lower extremity occlusive disease has long
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doi:10.1016/j.jvs.2007.05.059been considered open surgical bypass.1-4 Over the past
decade, however, there has been an increasingly rapid move
toward less invasive therapy through percutaneous endolu-
minal approaches to the management of this disease. While
balloon angioplasty and stenting was initially confined to
the iliac vessels, many groups have demonstrated consider-
able success with infra-inguinal percutaneous interven-
tion.5-10 A recent randomized trial of drug-coated and bare
nitinol stent placement in the superficial femoral artery
(SFA) revealed a restenosis rate of only 21.9% for both
therapies at 2 years.9 The comparison between bypass
surgery and balloon angioplasty has even been evaluated in
a prospective randomized manner in the Bypass Versus
Angioplasty for Severe Ischemia of the Leg (BASIL) Trial,
and these two modalities were found to be equivalent in
terms of amputation-free survival.10
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disease has evolved, the armamentarium available to the
vascular surgeon has grown considerably. No longer is
percutaneous therapy limited to balloon angioplasty, since
additional techniques such as laser angioplasty, cryoplasty,
atherectomy, and other adjuncts to endoluminal therapy
have become available.11-13 The broadened experience sur-
geons have acquired with percutaneous therapy has paral-
leled these technological advances and has allowed percu-
taneous intervention to evolve into a first-line modality for
limb-threatening ischemia in many centers. However, pa-
tients with limb-threatening ischemia are at increased risk
of treatment failure and have been shown to have reduced
patency rates compared with claudicants.6,14 While it is
unclear what factors lead to failure in these patients, the
difference in lesion severity and treatment complexity be-
tween these two distinct clinical groups may delineate this
issue further.
The TransAtlantic InterSociety Consensus (TASC)
classification was initially developed in the early 1990s and
later updated in order to provide a standardized grading
system for iliac and eventually femoropopliteal lesions, as
well as to provide guidelines for management of various
types and severity of lower extremity occlusive disease.15,16
Citing apparent reduced patency rates for long segment
occlusions, the original consensus statement on infra-
inguinal occlusive disease recommended in favor of surgical
bypass and against endovascular techniques for patients
with more advanced TASCC and D lesions.15,16 However,
at the time of these initial recommendations, available stent
types were limited to balloon expandable stainless steel
stents, and more recent publications have demonstrated
reasonable patency rates through endovascular treatment
of patients with advanced lesions.6
Similarly, early efforts with lower extremity endovascu-
lar techniques also tended to favor short segment disease in
a single level and those with more proximal disease (ie,
femoral or popliteal rather than tibial). As surgeons have
become more aggressive with endovascular therapy, treat-
ment strategies that include multilevel recannalizations and
intervention upon distal tibial disease have become more
common.
Although the literature on the iliac circulation has
supported the notion that patients with more severe
atherosclerotic disease may have poorer outcomes than
patients with less severe plaque burden,17a recent report
suggests that perhaps patency of successfully treated
vessels is not directly correlated to TASC classification or
lesion complexity.18 The relationship between severity of
underlying atherosclerotic disease and patency rates is
even less clear for infra-inguinal lesions and needs further
delineation in the literature. The purpose of this report
was to document the outcome of patients treated by
infra-inguinal percutaneous interventions and to exam-
ine the relationship between patency and lesion severity
or treatment complexity.METHODS
Patients who underwent percutaneous infra-inguinal
lower extremity revascularization for primary arterial le-
sions performed by the Division of Vascular Surgery be-
tween 2002 and 2005 were identified. Review of patient
charts, operative reports, pre- and postoperative studies,
and intraoperative angiograms were performed for all pa-
tients. Procedural indications included debilitating claudi-
cation (defined as severely impairing lifestyle and ranging
from 0.5 to 4 blocks) or limb-threatening ischemia (de-
fined as rest pain or tissue loss/ulceration). Patients were
excluded from analysis for prior bypass surgery (15 pa-
tients) or a presentation of acute lower extremity ischemia
(12 patients), and the study focused only on patients un-
dergoing percutaneous therapy as a first-line modality. All
patients were prospectively entered into a database along
with demographic information, comorbidities, and periop-
erative event data including complications and length of
hospital stay. Detailed operative reports (including lesion
severity, lesion length, and tibial runoff) and angiograms
were available and retrospectively reviewed for all interven-
tions to determine type and location of treated lesions.
Lesions included both stenoses and occlusions at all levels
(femoral, popliteal, and tibial). Angiograms were used to
stratify femoropopliteal lesions by TransAtlantic InterSoci-
ety Consensus (TASC) classification and to evaluate num-
ber of pre- and postoperative tibial runoff vessels.15 Review
of the Divisional Vascular Lab database allowed determina-
tion of pre- and postoperative noninvasive flow study pa-
rameters. Postoperatively, patients were followed by phys-
ical exam to assess pulses andwound healing, ankle-brachial
indices (ABI), and arterial duplex exam of the treated
region.
Percutaneous revascularization became increasingly re-
lied upon during the study period for patients with chronic
limb ischemia. Patients with isolated common femoral ar-
tery occlusions, behind the knee popliteal artery lesions, or
patients with advanced presentation of acute ischemia were
generally treated with surgical bypass and not considered in
this analysis. Percutaneous interventions included angio-
plasty with and without stent placement, cryoplasty balloon
angioplasty (generally for restenotic lesions), and laser an-
gioplasty. A contralateral retrograde approach was used in
the majority of interventions (69.3%), while an ipsilateral
antegrade approach was generally employed when isolated
tibial disease was anticipated from preoperative studies
(30.7%). Procedures were performed either with a portable
imaging fluoroscopic C-arm (OEC 9800; GEMedical Sys-
tems, Milwaukee, Wis) or in the angio-equipped operating
room using fixed fluoroscopic equipment (Siemens, Mu-
nich, Germany). Iodinated contrast was used in patients
with normal creatinine, and gadolinium or combination
gadolinium plus iodinated contrast was used in patients
with creatinine level greater that 1.3 mg/dl. All patients
were anticoagulated with intravenous heparin (100 units/
kg) after placement of a Balkin sheath (Cook, Blooming-
ton, Ind) for contralateral procedures or before crossing a
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clotting time was maintained above 250 seconds. The
majority of procedures were performed under local anes-
thesia with intravenous sedation. Aspirin was administered
to all patients postoperatively unless contra-indicated. For
patients undergoing stent placement, a loading dose of
plavix 450 mg was administered in the post-anesthesia care
unit (PACU), followed by 75 mg/day for 30 days.
Technique. Lesions were crossed with either luminal
or subintimal technique using hydrophilic guide wires
(0.035, 0.018, or 0.014 inch). Wires were supported using
4F and 5F angled glide catheters (Angiodynamics, Queens-
bury, NY) or Quick Cross catheters (Spectranetics, Colo-
rado Springs, Colo). Re-entry into the luminal space was
confirmed by angiography before further intervention. Bal-
loon angioplasty was performed with appropriately sized
noncompliant balloons for the treated vessel, with inflation
times ranging from 60 to120 seconds at 6 to 15 atm of
pressure. Stenting was performed selectively for 30% re-
sidual stenosis or flow limiting dissections. Completion
angiography with distal runoff was performed following
intervention.
Endpoints. Postoperative follow-up visits were per-
formed at 3-month intervals for the first year, then annually
thereafter. Patients underwent physical exam (assessing
pulse exam, wound healing, and presence of claudication or
rest pain) and vascular lab evaluation (for ankle-brachial
indices and arterial duplex ultrasound). Patency was pri-
marily determined by arterial duplex of the treated vessel
and secondarily by hemodynamic and clinical parameters if
arterial duplex results were not obtainable (in less than 20%
of patients). Loss of patency on arterial duplex was defined
as occlusion, 50% stenosis, or an elevated ratio of greater
than 4x the velocity of the more proximal segment. Hemo-
dynamic surrogates of patency loss included a decrease in
highest postoperative ABI by0.2 during follow-up or loss
of a previously palpable pulse. Clinical surrogates of pa-
tency loss included recurrence of claudication in claudicants
and failure of wound healing or need for major amputation
in patients with critical limb ischemia. In patients with
multilevel interventions, loss of patency at a single treated
level was considered failure for the entire limb, and patency
rates were analyzed by limb.
Statistical analysis. Demographic information was
tabulated for all patients and expressed as percentage 
standard deviation. Univariate analysis of dichotomous
variables between subgroups was performed by Fisher exact
t-test. Kaplan-Meier survival curves for primary and sec-
ondary patency and limb salvage rates were computed and
subgroups were compared by log-rank analysis to deter-
mine factors associated with treatment failure. Multivariate
analysis using Cox-logistic regression analysis was per-
formed to assess factors that were significant on univariate
analysis (Table II).
RESULTS
Patients. A total of 324 limbs in 258 patients were
analyzed from the period between 2002 and 2005. Withinthis group of patients, there were 284 primary procedures
and 40 re-interventions. Procedures were performed for
claudication (Rutherford category I, grade 2 to 3) in 55.8%
cases (181 limbs) and for limb-threatening ischemia in
44.1% (143 limbs). This latter group was divided between
patients with rest pain (Rutherford category II, grade 4) in
41.6%, and gangrene or tissue loss (Rutherford category
III, grade 5 to 6) in 58.4%. Patients presenting with acute
ischemia were excluded from analysis. Mean age was 72.1
 10 years (range 38 to 95 years), and 51.0% of patients
weremale. Comorbidmedical conditions included diabetes
in 61.2%, chronic renal insufficiency in 36.7%, end stage
renal disease/hemodialysis in 4.9%, hypertension in 80.9%,
history of tobacco use in 65.3%, hypercholesterolemia in
57.5%, and coronary artery disease in 58.6%.
Lesion characteristics. Review of lesion characteris-
tics as graded by TASC classification revealed predomi-
nately moderate to advanced disease as shown in Table I. In
claudicants as well as those with critical limb ischemia, a
paucity of TASC A lesions were encountered with much
larger numbers of TASC B to D lesions, showing the
relatively advanced degree of atherosclerosis of our patient
population. Lesions with higher TASC grade were signifi-
cantly more likely to occur in patients with limb-threaten-
ing ischemia (P .05, Table I). The femoral artery was the
location of the most commonly encountered lesions and
was treated in 89.2% of limbs. Popliteal lesions were treated
in 57.4% of limbs, and tibial lesions in 24.7%. Angioplasty
alone was more commonly performed than angioplasty
with stenting in the tibial (90.0% vs 10.0%, respectively)
and popliteal (54.4% vs 45.6%, respectively) circulations,
while angioplasty alone was less common than stenting in
the SFA (35.3% vs 64.7%). Treatment was performed for
single-level disease in 126 limbs (38.9%) and multilevel
disease in 197 limbs (60.8%, Table I). Multilevel interven-
tions were significantly more common in patients with
limb-threatening ischemia compared to claudicants (P 
.025). The level of the most distal intervention (femoral,
popliteal, or tibial) in each limb was also assessed and found
to vary significantly between patients with claudication
compared with those with critical limb ischemia (Table I).
Overall, 80 limbs (24.7%) had intervention at the tibial
level, while the remaining 244 limbs were almost equally
divided between femoral and popliteal regions as the most
distal treatment level. Claudicants had tibial interventions
in only 18.8% of limbs compared with 32.2% in patients
with critical limb ischemia (P .01). Tibial interventions in
claudicants were generally reserved for the purpose of im-
proving runoff in patients undergoing concomitant treat-
ment of SFA or popliteal lesions. Reduced tibial outflow
(three-vessel runoff vs three-vessel runoff) was also a
common finding, occurring in 79.6% of patients overall and
found with significantly increased prevalence in patients
with limb-threatening ischemia (P  .01).
Outcomes. Overall angiographic technical success
rate was 94.3% and did not significantly vary by lesion
location. Overall percutaneous re-intervention rate over
the follow-up period was 15.6%, with a mean follow-up of
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tients was 8.5 months. Local puncture site complications
were the most common complications, occurring in 13.2%
of limbs (9.3% groin hematoma, 3.9% pseudoaneurysm
formation). Closure devices were infrequently utilized and
puncture sites were managed primarily by pressure applica-
tion by housestaff. Review of local puncture site complica-
tions has subsequently led to the institution of a housestaff
certification process for sheath removal. Renal dysfunction
(defined as postprocedural increase in creatinine levels by
0.5 mg/dl) occurred in 6.0% and did not require dialysis in
any patient with a baseline Cr  4.0 mg/dl. Overall peri-
operative mortality (30-day) was 0.3%, and complication
rates did not vary by indication for intervention or treat-
ment level. Ten patients who had failed percutaneous treat-
ment for limb-threatening ischemia successfully underwent
surgical bypass for limb-salvage, and no patient was identi-
fied in which a more distal bypass was required because of
the failed percutaneous intervention. Thirteen patients un-
derwent major amputation after percutaneous intervention
because of failure of wound healing, sometimes with a
patent treated vessel. These 13 patients who underwent
amputation had no available options for surgical recon-
struction prior to percutaneous therapy. No patient who
presented with claudication required bypass or amputation.
Primary and secondary patency rates for all interven-
tions and limb-salvage rate for patients with critical limb
Table I. Lesion characteristics and procedure complexity
infra-inguinal revascularization
Claudication n (%)
N  181
TASC Classification*
TASC A 12 (6.6%)
TASC B 65 (35.9%)
TASC C 63 (34.8%)
TASC D 41 (22.7%)
# of Levels Treated
Single-level 81 (44.8%)
Two-level 80 (44.2%)
Three-level 20 (11.0%)
Most Distal Treatment Level
Femoral 77 (42.5%)
Popliteal 70 (38.7%)
Tibial 34 (18.8%)
*For femoropopliteal lesions.
Table II. Multivariate analysis of risk factors for reduced p
Odds Ra
Limb-threatening ischemia (indication) 1.75
Multi-level intervention 1.43
Tibial intervention 1.32
Reduced tibial outflow ( 3-vessel) —
TASC D (vs. TASC B/C) —ischemia (rest pain or tissue loss) are demonstrated byKaplan-Meier curves in Fig 1. For primary interventions,
overall 6-, 12-, and 18-month primary patency rates were
87  2%, 62  3%, and 59  3%, while secondary patency
rates were significantly higher at 89 2%, 76 3%, and 69
 7% (P  .001). Limb-salvage rates over the same inter-
vals were 94  2%, 85  4%, and 85  4%.
Stent placement was required in 64.7%, 45.6%, and
10.0% of femoral, popliteal, and tibial interventions, respec-
tively. Subgroup analysis by treatment modality was per-
formed and revealed no significant difference in primary
and secondary patency or limb-salvage rate in patients
treated with and without stent placement (P .05). There
were insufficient numbers of patients undergoing laser an-
gioplasty or re-intervention with cryoplasty to separately
analyze these patients on subgroup analysis. Thirty-four
patients had bilateral intervention (on separate occasions).
Bilaterality did not significantly effect primary, secondary,
or limb-salvage rates (P  .05).
Each of the four variables related to lesion severity and
treatment complexity that were found to exist with in-
creased prevalence in patients with limb-threatening isch-
emia also correlated with primary patency by univariate
analysis. These included TASC classification of the treated
lesions, the number of levels (femoral, popliteal, and tibial)
treated, the level of the most distal treated lesion, and tibial
vessel runoff. Increasing severity of TASC classification
(TASC A to TASC D) was inversely related to primary
bs (primary interventions) undergoing percutaneous
cal Limb Ischemia n (%) All n (%) P-value
N  143 N  324
4 (2.8%) 16 (4.9%) p  0.01
30 (20.9%) 95 (29.3%)
59 (41.3%) 122 (37.7%)
50 (35.0%) 91 (28.1%)
45 (31.4%) 126 (38.9%) p  0.025
69 (48.3%) 149 (46.2%)
29 (20.3%) 49 (14.9%)
42 (29.4%) 119 (36.7%) p  0.01
55 (38.4%) 125 (38.6%)
46 (32.2%) 80 (24.7%)
ry patency after percutaneous intervention
95% Confidence Interval P-value
1.1–2.6 0.01
1.1–1.9 0.02
1.0–1.7 0.04
— 0.20, ns
— 0.19, nsin lim
Critirima
tiopatency by log-rank analysis (Fig 2). Kaplan-Meier analysis
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lent patency rates, and the disparity in patency rates by
TASC classification was attributable to the difference be-
tween TASC A/B/C lesions compared to TASCD lesions.
The 6-, 12-, and 18-month primary patency rates were 88
 3%, 67 6%, and 63 9% for TASCA/B/C , compared
with 84 4%, 61 6%, and 48 3for TASC D (P .05,
Fig 2).Similarly, the total number of levels treated during
each intervention was inversely related to primary patency
(P  .002, Fig 3). Patients who underwent treatment in a
Fig 1. Primary and secondary patency rates for all interventions
and limb-salvage rates for patients with limb-threatening ischemia
expressed by Kaplan-Meier curves. The differences between each
curve were highly significant on log-rank analysis.
Fig 2. Primary patency rates for all treated limbs stratified by
TASC classification of lesions. Reduced patency was observed as
TASC severity increased.single level had 6-, 12-, and 18-month primary patencyrates of 91 3%, 76 5%, and 71 9%, compared with 73
 6%, 49 9%, and 42 10% in patients with treatment in
all three (femoral, popliteal, and tibial) levels (P .002, Fig
3). The location of the most distal treated lesion was also
related to patency, with patients undergoing tibial interven-
tions showing lower primary patency rates by Kaplan-Meier
method than those undergoing popliteal or femoral inter-
vention as their most distal area treated (P  .013, Fig 4).
For example, 1-year primary patency for those undergoing
tibial intervention was 57  7%, compared with 74  5%
for femoral intervention and 63  6% for popliteal inter-
vention as the most distal treatment site. Finally, the num-
ber of tibial runoff vessels correlated to patency as improved
primary patency was seen in patients with three-vessel run-
off (1-year patency of 83  6%) compared with those with
 three-vessel runoff (one-year patency of 52  6%, P 
.02). Several other patient-related variables were found to
correlate with reduced primary patency by Kaplan-Meier
method, including diabetes (P .05) and critical limb
ischemia (P  .002) as the indication for intervention.
Multivariate analysis revealed that limb-threatening
ischemia as an indication for intervention, multilevel inter-
vention, and distal tibial intervention remained indepen-
dently associated with primary patency, while the other
lesion- and treatment-related factors were not associated
with outcome (Table II).
Despite the correlation between each of these lesion
and treatment factors and primary patency, none correlated
with either secondary patency or limb-salvage rates (P 
.05). Number of levels treated showed a trend toward an
inverse correlation with patency, but this did not reach
statistical significance (P  .10). Of the patient-related
Fig 3. Primary patency rate by Kaplan-Meier method for all
treated limbs stratified by number of levels treated. There was an
inverse relationship between number of levels treated and primary
patency rate, which was highly significant.variables, only critical limb ischemia as an indication for
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tency rate (Fig 5, a and b, P  .02).
DISCUSSION
Percutaneous lower extremity revascularization for
chronic ischemia is becoming increasingly utilized by vas-
cular surgeons and is being applied not only to short
segment stenoses but also to chronic occlusions and long
segment lesions. Lipsitz et al reported the results of subin-
timal angioplasty in 39 patients with chronic total occlu-
sions, which included an 87% recannalization success rate
Fig 4. Primary patency rate of all treated limbs stratified by the
location of the most distal intervention (femoral, popliteal, or
tibial) and expressed by Kaplan-Meier method. Tibial interven-
tions were significantly correlated with reduced primary patency.
Fig 5. a, Primary and b, secondary patency rates for all patients
stratified by indication for intervention (claudication vs limb-
threatening ischemia). Limb-threatening ischemia as an indication
for intervention was the single most important determinant of
outcome and was associated with reduced primary and secondary
patency rates.and 74% patency at 12 months.19 The BASIL trial studiedthe use of angioplasty compared with surgical bypass in a
prospective randomized manner in patients with limb-
threatening ischemia, who typically have complex lesions
and severe disease.19 This group found equivalent amputa-
tion-free survival between the two modalities and even
demonstrated lower first-year hospital costs with an endo-
vascular-first strategy.
Another important randomized trial examined the use
of primary stenting as opposed to selective stenting for
residual stenosis after balloon angioplasty.7Previous reports
addressing the questionable durability of endovascular pro-
cedures and the effect of stent fractures on patency of the
treated region led to the desire to clarify the optimal
endovascular strategy.9,20 In Schillinger et al, primary stent
implantation rather than selective stenting after balloon
angioplasty was found to result in superior patency rates,
and this benefit has been sustained at 2-year follow-up.7,21
In the current study, there was no significant difference in
primary patency between patients who did and did not
receive stents. However, as this was a retrospective analysis,
there is likely considerable treatment selection bias between
these two groups.
Despite the encouraging results of percutaneous ther-
apy for lower extremity occlusive disease, there is consider-
able variability in the severity of lesions and the outcomes
obtained between different groups of patients, and it is
unclear whether some subgroups of patients or some
lesion-types may be better suited for open surgical revascu-
larization.
The patients described in this report represent a popu-
lation with considerable atherosclerotic disease burden, as
evidenced by the predominance of TASC B through D
lesions and relatively few TASC A lesions. Furthermore,
almost two thirds of the patients had multilevel disease
requiring intervention, and greater than 25% required in-
tervention at the tibial level. The high percentage of pa-
tients with advanced disease is attributable to the preva-
lence of cardiovascular risk factors in the surrounding
catchment area and the fact that our institution serves as a
major tertiary referral center from a number of other re-
gions. Furthermore, all of these patients underwent inter-
vention by members of the Division of Vascular Surgery,
and this patient population may reflect the fact that patients
who present or are referred to vascular surgeons more
commonly have ulceration or gangrene than patients
treated by other non-surgeon interventionalists. The high
incidence of advanced lesions is not uncommon in reports
by other surgical groups, although lesion severity can range
substantially.5,6,22-24 Black and colleagues, for example,
had slightly less severe TASC grades than the current study
(47.5% TASC C or D lesions compared to 65.4%), but had
a larger number of patients with tibial level interventions
(37% compared with 25.6%).6 Studies focusing on patients
with critical limb ischemia not surprisingly report a higher
proportion of TASC C and D lesions, such as Kudo and
colleagues who found these advanced lesions in 89% of
patients with critical limb ischemia.5
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mary patency was the indication for intervention. Patients
with limb-threatening ischemia (either rest pain or tissue
loss) had a significantly reduced primary and secondary
patency by Kaplan-Meier analysis than those presenting
with claudication. This association has clearly been shown
by other groups as well.14,22,25-26In fact, the poorer out-
comes in these patients have led some to argue in favor of
surgical bypass as the preferred modality of treatment for
limb-threatening ischemia, with percutaneous intervention
reserved for nonsurgical candidates or those with short-
segment occlusions.14 In our patients, this association is
likely related to four other lesion- and treatment-related
characteristics found more often in patients with limb-
threatening ischemia. Specifically, patients with limb-
threatening ischemia were significantly more likely to have
TASC D lesions, multilevel interventions, tibial interven-
tions, and reduced tibial outflow than claudicants (Table I).
Each of these individual factors was found to be associated
with reduced primary patency in subgroup analysis.
The effect of TASC classification on patency has been
examined by other groups as well. Suroweic and colleagues
found that patency was highly dependent on TASC classi-
fication in 380 limbs undergoing percutaneous angioplasty
and stenting of the superficial femoral artery.22 Patients
with TASC A and B lesions had patency rates of 90% and
85%, respectively, which were comparable to their results
with surgical bypass. Conversely, patients with TASCC and
D lesions had patency rates of 70% and 50%, respectively,
which were significantly inferior to bypass. Similarly, Kudo
and colleagues have demonstrated that TASC D lesions
(compared with TASC C and B) portend a significantly
worse outcome in terms of both primary and secondary
patency, with hazard ratios of 4.6 and 12.8, respectively.
This is a finding, which is analogous to the inverse relation-
ship between TASC classification and patency in iliac le-
sions, a finding, which has been commonly, although not
universally, demonstrated.17,18 In our study, there was an
inverse relationship between TASC D lesions (compared
with TASC A/B/C) and primary patency (Fig 2).
Intervention at multiple levels was strongly associ-
ated with reduced primary patency in this series. Al-
though the location of the treated levels was also relevant
to patency, multilevel treatment alone conferred an in-
creased risk of failure. It is likely that treatment at
multiple levels is an indicator of diffuse atherosclerosis
and underlying multilevel disease. Failure in these pa-
tients can be from restenosis of the treated area or
progression of their systemic disease process. Similar
findings were attained by Kudo et al who found that the
number of levels treated and the level of the most distal
intervention were independent risk factors for reduced
patency on both univariate and multivariate analysis.7
The most distal level of intervention was also found to
be significantly associated with patency in this study (Fig 4).
One-year patency in our patients with tibial interventions
was substantially less than those with more proximal disease
regardless of type of treatment or other patient variables.All of these factors indicate increased lesion severity and
treatment complexity. These variables were also more com-
monly found in those with limb-threatening ischemia, and
this fact can largely explain the poorer outcomes in these
patients compared with patients with claudication. How-
ever, it is important to note than while primary patency was
reduced in patients with these factors, secondary patency
and limb salvage was equivalent regardless of TASC classi-
fication, number of treated levels, level of the most distal
lesions treated, or tibial outflow. Therefore, while these
patients with severe disease and increased treatment com-
plexity can expect to have an increased chance of an initial
failure, they can undergo repeat intervention successfully
and benefit from a secondary patency rate equivalent to
those with less severe disease. Similarly, the limb-salvage
rate in this group may remain equivalent to those less
complex lesions. Ultimately, patients with higher TASC
classification, multi-level disease, and more distal interven-
tions can be expected to have similar outcomes to other
patients, albeit with the understanding that they may have
higher re-intervention rates. This finding is congruent with
other reports, which have found that loss of primary pa-
tency is not necessarily associated with a reduction in limb
salvage, and that initial failure of percutaneous treatment
does not obligatorily result in loss of collateral vessels,
recurrence of limb-threat, or recurrence of claudication
symptoms.27
Although our database is maintained in a prospective
manner, one of the major weaknesses of this study includes
the retrospective nature of the review of angiograms and
operative reports for the grading of lesion types and sever-
ity. Prospectively assessing and recording such parameters
as lesion lengths, lesion types, tibial outflow, and TASC
classification would further assure accuracy and reproduc-
ibility of these findings and should be considered the goal
for studies of these modalities.
CONCLUSION
Percutaneous intervention has become increasingly uti-
lized for lower extremity occlusive disease in recent years, as
these modalities are less invasive and generally less morbid
than open surgical techniques. Lesion characteristics such
as TASC classification and other indicators of severe and
complex disease affect primary patency rates of percutane-
ous interventions. Taken separately, however, these factors
do not appear to affect secondary patency or limb-salvage
rates, indicating that these patients may share similar out-
comes as those with less severe disease following re-inter-
vention after an initial failure. The poorer outcome in
patients with limb-threatening ischemia is likely a result of
the composite effect of several of these factors as well as
other yet undiscovered patient and lesion characteristics.
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